文献速递肾小球疾病急性肾损伤

免疫检查点抑制剂相关肾小球疾病的系统综述

A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.
PubMed 文献 · Kidney Int Rep · 2020-10-16

该研究系统综述了免疫检查点抑制剂(ICI)相关肾小球疾病的病理类型、治疗与结局。纳入45例经活检证实的病例,最常见为寡免疫复合物肾小球肾炎和肾血管炎(27%)、足细胞病(24%)及C3肾小球肾炎(11%),41%合并急性间质性肾炎。多数患者停用ICI并接受糖皮质激素,但肾脏及死亡结局较差。

要点

  • ICI相关肾小球疾病病理类型多样,以寡免疫复合物GN/血管炎、足细胞病和C3GN最常见。
  • 41%的病例合并急性间质性肾炎,提示肾活检对鉴别诊断重要。
  • 尽管多数患者停用ICI并使用激素,仍有19%依赖透析,约三分之一死亡。

核心结论

  • ICI相关肾小球疾病包含多种病理类型,以寡免疫复合物GN、足细胞病和C3GN报告最多。
  • 该类疾病可能与较差的肾脏结局和死亡率相关。
  • 肿瘤科和肾内科医生应认识ICI相关肾小球病变,当表现不典型于AIN时考虑肾活检。

研究设计与样本

  • 系统综述与meta分析,检索MEDLINE、EMBASE和Cochrane数据库自建库至2020年2月。
  • 纳入经活检证实的ICI相关肾小球疾病已发表病例或系列,共27篇文章、45例病例。

主要发现

  • 病变类型:寡免疫复合物GN和肾血管炎占27%,足细胞病占24%,C3GN占11%。
  • 41%的病例合并急性间质性肾炎(AIN)。
  • 88%的患者停用ICI,98%接受糖皮质激素治疗,25%需要肾脏替代治疗(RRT)。
  • AKI完全恢复占31%,部分恢复占42%,19%仍依赖透析,约三分之一死亡。
  • 蛋白尿完全缓解占45%,部分缓解占38%。

临床怎么用

  • 对使用ICI并出现肾脏损伤的患者,若临床特征不典型于AIN,应考虑肾活检以明确肾小球病变。
  • ICI相关肾小球疾病患者可能需要停用ICI并接受糖皮质激素治疗,但需警惕肾脏及死亡风险。

局限性

  • 仅纳入已发表的经活检证实的病例/系列,可能存在发表偏倚。
  • 样本量较小(45例),且为回顾性病例汇总,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers. Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence of IRAEs ranging from 2% to 5%. Most of the initial data related to kidney IRAEs have focused on acute interstitial nephritis (AIN). There are minimal data on the types and relative frequencies of glomerular diseases associated with ICIs, their treatment, and outcomes. METHODS: We performed a systematic review and meta-analysis of all biopsy-proven published cases/series of glomerular pathology associated with ICIs. We searched the MEDLINE, EMBASE, and Cochrane databases from inception to February 2020. We abstracted patient-level data, including demographics, cancer and ICI therapy details, and characteristics of kidney injury. RESULTS: After screening, 27 articles with 45 cases of biopsy-confirmed ICI-associated glomerular disease were identified. Several lesion types were observed, with the most frequent being pauci-immune glomerulonephritis (GN) and renal vasculitis (27%), podocytopathies (24%), and complement 3 GN (C3GN; 11%). Concomitant AIN was reported in 41%. Most patients had ICIs discontinued (88%), and nearly all received corticosteroid treatment (98%). Renal replacement therapy (RRT) was required in 25%. Most patients had full (31%) or partial (42%) recovery from acute kidney injury (AKI), although 19% remained dialysis-dependent, and approximately one-third died. Complete or partial remission of proteinuria was achieved in 45% and 38%, respectively. CONCLUSION: Multiple forms of ICI-associated glomerular disease have been described. Pauci-immune GN, podocytopathies, and C3GN are the most frequently reported lesions. ICI-associated glomerular disease may be associated with poor kidney and mortality outcomes. Oncologists and nephrologists must be aware of glomerular pathologies associated with ICIs and consider obtaining a kidney biopsy specimen when features atypical for AIN are present.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kitchlu A, Jhaveri KD, Wadhwani S, et al. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2020. PMID: 33426386. doi:10.1016/j.ekir.2020.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。